NEW YORK (GenomeWeb) – Illumina and molecular diagnostics firm Burning Rock announced today that they will codevelop oncology products based on Illumina's sequencing instruments for the Chinese market.

As part of the agreement, Illumina will provide NGS instrument components and reagents and Guangzhou, China-based Burning Rock will provide its nucleic acid extraction, library preparation, and data analysis software.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.